Edition:
India

H Lundbeck A/S (LUN.CO)

LUN.CO on Copenhagen Stock Exchange

448.30DKK
17 Jul 2018
Change (% chg)

-- (--)
Prev Close
kr.448.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
344,696
52-wk High
kr.477.70
52-wk Low
kr.280.80

Chart for

About

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and... (more)

Overall

Beta: 0.88
Market Cap(Mil.): kr.87,909.02
Shares Outstanding(Mil.): 199.10
Dividend: 8.00
Yield (%): 1.80

Financials

  LUN.CO Industry Sector
P/E (TTM): 27.21 29.21 33.15
EPS (TTM): 16.32 -- --
ROI: 25.58 13.66 13.23
ROE: 30.17 15.51 15.27

UPDATE 1-Drugmaker Lundbeck to settle U.S. charity probe for $52.6 mln

BOSTON, June 6 Danish drugmaker Lundbeck said on Wednesday that it will pay $52.6 million to resolve a U.S. probe into its financial support of patient assistance charitable foundations.

07 Jun 2018

Drugmaker Lundbeck to settle U.S. charity probe for $52.6 mln

BOSTON, June 6 Danish drugmaker Lundbeck said on Wednesday that it had reached a deal to pay $52.6 million to resolve a U.S. probe into its financial support of patient assistance charitable foundations.

07 Jun 2018

BRIEF-H Lundbeck says FDA updates Trintellix label to include data showing improvement in processing speed

* REG-FDA UPDATES TRINTELLIX® (VORTIOXETINE) LABEL TO INCLUDE DATA SHOWING IMPROVEMENT IN PROCESSING SPEED, AN IMPORTANT ASPECT OF COGNITIVE FUNCTION IN ACUTE MAJOR DEPRESSIVE DISORDER (MDD)

03 May 2018

BRIEF-Lundbeck Says New CEO To Be Named Within Six Months

* INTERIM CEO GOTZSCHE SAYS EXPECTS NEW CEO WILL BE NAMED WITHIN SIX MONTHS

07 Feb 2018

UPDATE 1-Lundbeck's Q4 operating profit falls short of expectations

COPENHAGEN, Feb 7 Danish drugmaker Lundbeck posted weaker than expected fourth quarter operating profit and gave a broad range for its 2018 financial guidance because of a range of uncertainties.

07 Feb 2018

Lundbeck's Q4 operating profit below expectations

COPENHAGEN, Feb 7 Drugmaker Lundbeck's fourth-quarter operating profit came in at 932 million Danish crowns ($155.19 million), undershooting the 1.05 billion expected by analysts in a Reuters poll.

07 Feb 2018

Earnings vs. Estimates